AI for Pharma Companies in 2027: Choose the First Use Case Before the Vendor

Why AI Pilots Are Harder in Pharma Than Elsewhere

Most pharmaceutical companies do not lack AI tools. They lack a clear basis for choosing among them. Every month brings new tools for drug discovery, pharmacovigilance, medical content, and regulatory writing, and each demo is persuasive. Teams often buy a platform before deciding which workflow it should serve. Six months later the validation documents are incomplete, data access requests are still waiting for approval, and nobody can say how much time the tool actually saved. By 2027, the more useful question is not whether AI fits pharma, but which workflow to start with, how to rank the candidates, and how to choose a vendor that can withstand GxP scrutiny.

A pilot that succeeds in a marketing team or a contact center cannot simply be copied into a pharmaceutical company. Pharma outputs can end up in regulatory submissions, safety reports, batch records, or medical responses. These documents carry audit trail, validation, and accountability requirements that general-purpose chatbots were never designed to meet. Patient data adds privacy obligations, and cross-border data transfers add another layer of review.

This means wrong answers are more costly, and proving that answers are right is more expensive. Teams that ignore this reality usually discover it late, often when quality or regulatory colleagues ask for evidence that the tool behaves consistently. Before comparing any products, write down who will be accountable for the output and what evidence they will need before they sign off.

Mapping Realistic Use Case Categories

Most pharma AI work clusters around a small number of workflows. This list is not exhaustive, but it covers most of the requests that reach digital or quality teams:

- Pharmacovigilance support, such as intake triage for case reports or literature screening for safety signals, with final decisions always made by a human reviewer. - Drafting assistance for regulatory and clinical documents, such as first drafts of sections generated from approved source documents. - Quality management retrieval, such as answering questions from SOPs, deviation records, and CAPA history, with citations to the underlying sources. - Review of medical information and promotional materials, such as checking draft materials against the approved label and internal rules. - Summaries of production records, such as condensing batch records or investigation files for quality reviewers. - Supply chain signals, such as flagging demand or inventory anomalies for planners.

The mistake is to treat all of these as one category called "pharma AI." Each has different data, different reviewers, and different risks. A literature screening tool and a production deviation summarizer may use similar underlying technology, yet the depth of validation each requires is entirely different.

Ranking by Value and Difficulty, Not Enthusiasm

Once you have a list of candidates, score each one on two dimensions. Value includes the hours saved per cycle, shorter review or submission timelines, fewer rework loops, and lower compliance risk. Difficulty includes data readiness, validation burden, the degree of patient impact, integration with existing systems, and how many approvals the workflow requires.

A practical habit is to score every candidate on the same five-point scale and write one sentence explaining each score. If you cannot explain why a use case is high value, it is probably not ready for a pilot. If a difficulty score depends on a system nobody has checked, mark it as unknown rather than low. The internal guide Use Case Prioritization Method on this site is a reasonable template for building this table.

In most pharmaceutical organizations, high-value projects tend to sit close to regulated outputs, which makes them harder to launch. This is normal. The goal of ranking is to find the intersection of meaningful time savings and controllable risk, not to avoid risk altogether.

Choosing a First Pilot That Can Fail Safely

The best first pilot in a pharmaceutical company usually has a few features: it is internal, keeps a human reviewer in the loop, uses documents the company already owns, and has a measurable baseline. Literature screening support for a safety team is a common example. You can take a fixed sample of articles that reviewers have already classified, run the tool on the same articles, and compare its suggestions with the human decisions. The pilot does not need to replace any reviewer. It only needs to show where the tool agrees, where it misses, and how reviewer time changes.

Avoid starting with anything that generates patient-facing text, dosing guidance, or final regulatory statements. These use cases may become valuable later, but they require substantial validation work, and a first pilot rarely has that margin.

When you define the pilot, record four things: the workflow owner, the reviewer who checks the output, the sample set, and the stop conditions. Clear stop conditions, such as triggering a redesign if the number of missed items exceeds a set threshold, are far more useful than a vague instruction to "see how it goes."

This is also the point where teams move from planning to execution. If you want to run this kind of structured pilot in one place, including the use case list, scoring, and pilot tracking, you can sign up for a trial at Duaer and set up the workflow there. The platform helps organize the process, but it does not replace your own validation or reviewer sign-off, so treat it as a tool for keeping the pilot disciplined rather than as a shortcut.

Evaluating Vendors Against Pharma-Specific Criteria

Generic vendor scorecards often miss the questions that pharma teams need answered. Before signing any agreement, check the following areas:

- Data handling: where data is processed and stored, who can access it, and whether your documents are used to train shared models. - Validation support: whether the vendor provides documentation you can adapt for your own validation plan, rather than only a marketing statement that the system is "compliant." - Audit trail: whether every input, output, and user action is logged in a form the quality team can review. - Change control: how model or software updates are announced, tested, and locked in your environment. - Testability: whether you can run the tool on your own de-identified documents during evaluation, not just on the vendor's sample set. - Exit terms: how you retrieve your data, configurations, and logs if you change vendors.

The AI Vendor Evaluation Checklist is a good companion tool here. Ask every vendor to answer the same questions in writing. Vague answers are also information.

Measuring the Pilot in Ways Reviewers Will Accept

A pilot that reports only enthusiasm will not survive a budget review. Measure at least five things: accuracy relative to the reviewer baseline, the share of outputs that need correction, review time per item before and after the pilot, the number of quality or compliance issues raised during the pilot, and whether the target users are still using the tool after the first few weeks.

Do not set targets before you know the baseline. Many teams set ambitious accuracy goals and then discover that human reviewers disagree with one another more than expected. Measuring agreement between reviewers is often the most valuable early output of a pilot.

One Thing to Do This Week

Pick three workflows in your organization that involve regulated documents, safety review, or quality review. Score each one for value and difficulty using the same scale. Then write a one-page pilot charter for the workflow with the best combination of value and manageable difficulty, stating the owner, the reviewers, the sample set, and the stop conditions. Before speaking with any vendor, send the charter to your quality or regulatory lead. The objections they raise will reveal the real constraints more clearly than any product brochure.

If you are ready to turn this charter into a working process, you can sign up for a trial at https://www.duaer.com and test the workflow using your own non-sensitive sample documents first.

Success with AI in pharma depends on choosing the first use case for its evidence and controllability, not its novelty. Start with a workflow you can measure, keep a human accountable for every regulated output, and let vendors earn their place through testing on your own documents.